Pathol Lab News Today

Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant... | April 16, 2023

Approval based on DESTINY-Breast04 results where Daiichi Sankyo and AstraZeneca's ENHERTU reduced the risk of disease progression or death by 50% and increased median overall survival by more than

Investegate announcements from AstraZeneca PLC, Enhertu recommended for EU approval in HER2-low BC

DESTINY-Lung02 phase 2 trial shows clinically meaningful efficacy and favorable safety at 5.4 mg/kg dose versus 6.4 mg/kg dose of Daiichi Sankyo and A

Application based on DESTINY-Breast04 results that showed Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan demonstrated superior progression-free and overall survival versus chemotherapy Daiichi

Daiichi Sankyo and AstraZeneca's ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 5, 2022--

AstraZeneca and Daiichi Sankyo’s Enhertu has been granted Breakthrough Therapy Designation in the US for the treatment of adult patients with unresectable or...

Researchers stress the importance of vaccination for pregnant women to avoid catastrophic outcomes of childbirth.

Since the beginning of the COVID-19 pandemic, in-utero transmission of SARS-CoV-2 remains a rarity and only very few cases have been proven across the world. Here we depict the clinical, laboratory and radiologic findings of preterm triplets born at 28 6/7 weeks to a mother who contracted COVID-19 just one week before delivery. The triplets showed SARS-CoV-2 positivity right after birth, developed significant leukopenia and early-onset pulmonary interstitial emphysema. The most severely affected...